Physician profile
Allison L Key
NPI 1871781476
$7,668.00
in general payments reported to CMS, 2019-2025
44 companies · $754 in 2025
The $754 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,457 · 2020: $843 · 2021: $1,057 · 2022: $669 · 2023: $2,000 · 2024: $889 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,946 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,945.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,696.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,375.27 | 2019-2025 | |
| Novo Nordisk INC | $612.66 | 2019-2023 | Rybelsus, Ozempic |
| Amgen INC. | $464.94 | 2019-2025 | Tepezza |
| Allergan, INC. | $379.68 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $324.87 | 2019-2022 | |
| Astellas Pharma US INC | $298.72 | 2019-2025 | Veozah |
| Merz North America, INC. | $264.22 | 2019-2021 | |
| Amarin Pharma, INC. | $259.83 | 2019-2021 | |
| Glaxosmithkline, LLC. | $182.60 | 2019-2025 | Bexsero, Penmenvy |
| Pfizer INC. | $157.07 | 2019-2024 | |
| Lilly USA, LLC | $122.50 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.80 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $114.81 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $109.41 | 2019-2023 | Rexulti |
| Supernus Pharmaceuticals, INC. | $90.34 | 2021-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Key listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.